Skip to content
Suven Pharma
  • About Us
    • Mission, Vision & Values
    • Why Suven ?
    • Background
    • Our Journey
    • Quality
    • Code of Conduct
    • Board of Directors, Management & Advisory Council
  • Research & Facilities
  • Business Segments
    • Formulation Development and Analytical services
    • Process Research
    • Custom Synthesis
    • Clinical supplies Manufacturing and Packaging
  • Investors
    • Financial Info
    • Share Holder’s Info
    • Corporate Governance
    • Corporate Info
    • Disclosure under Reg 46 of SEBI LODR
  • Sustainability
    • IMS Policy
    • CSR Policy
    • CSR Projects
    • CSR Gallery
    • Certification
    • BRSR Policies
    • Policies
  • ESG
    • Reports & Disclosures
    • ESG Profile
  • Contact Us

admin-suven

Suven Pharma zooms 12% on merger with Cohance Lifesciences

01 03/2024 by admin-suven
Categories Recent News Leave a comment

Cohance Lifesciences to merge with Suven Pharma

01 03/2024 by admin-suven
Categories Recent News Leave a comment

Advent PE begins merger process of Suven Pharma and Cohance Lifesciences

01 03/2024 by admin-suven
Categories Recent News Leave a comment

Suven Pharma Q2 results: Net profit up 10% YoY to Rs 79.5 crore – Copy

03 01/202410 11/2023 by admin-suven
Categories Recent News Leave a comment

Suven Pharma Q2 net rises 10%, inventory de-stocking impacts revenue

10 11/2023 by admin-suven
The Hindu
Categories Recent News Leave a comment

Advent acquires 50.1% in Suven Pharma, open offer for additional 26% ahead

29 09/2023 by admin-suven
Advent International Announces
Categories Recent News Leave a comment

Advent puts in place a new team to helm Suven Pharma

29 09/2023 by admin-suven
Categories Recent News Leave a comment

PE firm Advent acquires 50.1% stake in Suven Pharma at Rs 495/share, to make open offer for additional 26% stake

29 09/2023 by admin-suven
Categories Recent News Leave a comment

Cabinet okays FDI of up to Rs 9,589 crore for 76.1% stake in Hyderabad-based Suven Pharma

29 09/2023 by admin-suven
Categories Recent News Leave a comment

Suven Pharma acquires Hyd-based Casper Pharma for Rs 155 Cr

10 10/2022 by admin-suven
Categories Recent News Leave a comment
Older posts
Page1 Page2 Next →
Suven Pharma

World class manufacturing facilities in the business of Pharmaceuticals and Fine Chemical Intermediates for Global Pharma Companies for New Chemical Entities (NCE’s) as the thrust area. 

Quick Links

About Us

Research & Facilities

Business Segments

Investors

Sustainability & Social Responsibility

Corporate Office :

Suven Pharmaceuticals Ltd.

202, A-Wing, Galaxy Towers, Plot No-1, Hyderabad Knowledge City, TSIIC, Raidurg, Serilingampally, Rangareddy District, Hyderabad-500081 Telangana, India

+91-40-2354-9414 /3311

info@suvenpharm.com

Registered Office:

Suven Pharmaceuticals Ltd.

215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai- 400093, Maharashtra, India

CIN : L24299MH2018PLC422236

Reach Us | Terms Of Use | Privacy Policy
Suven Pharma

World class manufacturing facilities in the business of Pharmaceuticals and Fine Chemical Intermediates for Global Pharma Companies for New Chemical Entities (NCE’s) as the thrust area. 

Quick Links

About Us

Research & Facilities

Business Segments

Investors

Sustainability & Social Responsibility

Corporate Office :

Suven Pharmaceuticals Ltd.

202, A-Wing, Galaxy Towers, Plot No-1, Hyderabad Knowledge City, TSIIC, Raidurg, Serilingampally, Rangareddy District, Hyderabad-500081 Telangana, INDIA.

+91-40-2354-9414 /1142 /3311

info@suvenpharm.com

CIN : L24299MH2018PLC422236

Registered Office:

Suven Pharmaceuticals Ltd.

215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai- 400093, Maharashtra, India

Reach Us | Terms Of Use | Privacy Policy